Form 4 Neumora Therapeutics, For: Aug 27 Filed by: Pinto Joshua
Neumora Therapeutics, Inc. (NMRA)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
NMRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NMRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NMRA alerts
High impacting Neumora Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NMRA
News
- Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.MarketBeat
- Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Neumora Therapeutics to Participate in Upcoming Conferences in NovemberGlobeNewswire
- Neumora Therapeutics, Inc. (NASDAQ: NMRA) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $15.00 price target on the stock, down previously from $18.00.MarketBeat
NMRA
Earnings
- 11/12/24 - Miss
NMRA
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- NMRA's page on the SEC website